A Study of Panobinostat (LBH589) as Second-Line Therapy in Patients With Chronic Graft-Versus-Host Disease
Status:
Withdrawn
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
There is a clear need for effective, steroid-sparing agents for the management of chronic
graft-versus-host disease (GVHD). Thus, agents like Histone deacetylase (HDAC) inhibitors,
with the potential of decreasing pro-inflammatory events leading to GVHD without affecting
graft-versus-leukemia (GVL), may have a central role in the prevention and treatment of GVHD.
This study will look at the efficacy of panobinostat (LBH589), an HDAC inhibitor, in the
treatment of patients with chronic GVHD who have failed corticosteroids. In this group of
patients, effective steroid-sparing options are limited and are usually associated with
profound immunosuppression and decreased GVL effect.